Massive Bio ads

Massive Bio has introduced Reticulum Nexus, our new multi-agent platform built to coordinate the entire oncology journey, from first contact to last-mile enrollment, at global scale. It brings together clinical, operational, and AI intelligence into one system designed to remove fragmentation and make access to clinical trials more transparent, efficient, and patient-first. Read the full announcement here: https://lnkd.in/du36DVrv Selin Kurnaz, PhD | Arturo LoAIza-Bonilla MD | Çağatay M. Çulcuoğlu

In the latest Back of the Cab update, our Co-Founder and CEO Selin Kurnaz, PhD shares what conversations with #investors, #partners, and #technologyleaders look like across San Francisco TECH WEEK by a16z, the Longevity Global Brain Optimization Summit, the Clinical Trial Innovation Summit by PanAgora Pharma, and the Rock Health Summit, all shaping where AI and healthcare go next. For life sciences organizations, the questions raised in these rooms are increasingly practical. How does AI strengthen real-world data? How does that data inform trial design and evidence generation across the pharmaceutical lifecycle? Massive Bio sits at that intersection, connecting patient-consented real-world data and AI-driven oncology trial matching with the partners who put them to work. As Massive Bio continues to grow and build, more updates are on the way. #RealWorldData #RWD #LifeSciences #Pharma #Oncology #AIinHealthcare #DigitalHealth #SFTechWeek #ClinicalTrials #RockHealth Selin Kurnaz, PhD | Arturo LoAIza-Bonilla MD | Çağatay M. Çulcuoğlu

Massive Bio has been named to TIME's World's Top HealthTech Companies 2026 in the AI & Data Analytics category, produced in collaboration with Statista, which recognizes 500 companies worldwide based on financial performance, reputation, and online engagement. Massive Bio is in the company of leading innovators like Datavant, HealthVerity, IQVIA, ConcertAI, Tempus AI, Komodo Health, SOPHiA GENETICS, and Siemens Healthineers, among others, on this year's list. The recognition reflects Massive Bio's growing role as oncology data and AI infrastructure, bringing together patient-consented clinical and molecular data, specialized AI agents, and a global network of patients, physicians, and life sciences organizations. At the center of this is Reticulum Nexus (RNex), our multi-agent AI platform, developed as an oncology agent foundry that connects changes in diagnosis, biomarkers, treatment, and access barriers to the next appropriate action, while preserving clinical context throughout a patient's journey. Massive Bio has onboarded more than 200,000 cancer patients across 17 countries. A peer-reviewed evaluation of its AI-assisted trial-matching workflow, published in ESMO - European Society for Medical Oncology Real World Data and Digital Oncology, covered 3,804 patients, processed more than 157,000 pages of clinical documentation, and reported more than 17,000 oncologist-confirmed matches. Read more: https://lnkd.in/e5nycEuH #TIMEHealthTech2026 #OncologyAI #RealWorldData #PrecisionMedicine Selin Kurnaz, PhD | Arturo LoAIza-Bonilla MD | Çağatay M. Çulcuoğlu

Massive Bio has been named to TIME's World's Top HealthTech Companies of 2026, in the AI & Data Analytics category, in the company of leading innovators like Abridge, Viz.ai, Hinge Health, Maven Clinic, Prenuvo and many more. The recognition reflects a broader shift across the industry, where sponsors, CROs, and site networks are increasingly turning to AI-driven trial matching to move faster: quicker identification of eligible patients, reduced screen-fail rates, and access to community oncology populations that traditional recruitment channels often miss. Massive Bio uses AI-driven, real-world data solutions to streamline the patient journey, enhance access to advanced options, and optimize clinical trials for pharmaceutical companies, research organizations, and healthcare institutions. World's Top HealthTech Companies of 2026: https://lnkd.in/gMr_6s_V #PrecisionMedicine #DigitalHealth #PharmaInnovation #RWD #ClinicalOperations #TIME100 #CancerResearch Selin Kurnaz, PhD | Arturo LoAIza-Bonilla MD | Çağatay M. Çulcuoğlu

Our Co-Founder and CEO Selin Kurnaz, PhD has been selected among this year's 100 Most Influential Turks in America for her extraordinary accomplishments, alongside Nobel laureate Aziz Sancar, CMS (Centers for Medicare & Medicaid Services) Administrator Dr. Mehmet Oz, Hamdi Ulukaya of Chobani, Osman Kibar of Samumed, Aydin Senkut of Felicis Ventures, Eren Ozmen of Sierra Space, and Houston Rockets center Alperen Şengün. The Turk of America (TOA) Awards 2026 recognize individuals across 24 categories for their leadership, achievements, and impact in business, science, technology, academia, arts, media, and public service. This year's honorees were selected from a pool that started in the thousands, was narrowed to 500, and then selected down to the final 100. Congratulations to everyone selected this year. Massive Bio is proud to be counted among the companies and leaders shaping this list, and we remain committed to disrupting cancer care, AI-driven drug development and discovery, and improving cancer patients' lives. Selin will accept her award at the TOA Awards 2026 Gala on November 17 in Garfield, New Jersey, bringing together honorees from business, science, technology, government, media, and the arts. #TOAAwards2026 #Leadership #Entrepreneurship #Healthcare #PrecisionOncology #Cancer #HealthTech #AI TURKOFAMERICA Magazine - Cemil Ozyurt Selin Kurnaz, PhD | Arturo LoAIza-Bonilla MD | Çağatay M. Çulcuoğlu

AI is starting to close a long-standing gap in cancer care: connecting patients to the right clinical trial, faster and at scale. Our Co-Founder and CEO Selin Kurnaz, PhD joined Saul W. Marquez on the Outcomes Rocket podcast to talk about how Massive Bio is putting that idea into practice, using AI agents, conversational technology, and technology partnerships to build a scalable, end-to-end journey for cancer patients, regardless of where they live or what they can afford. Selin also shares her vision for Massive Bio as both a global access point for patients and a real-world data infrastructure that helps pharmaceutical companies develop more personalized medicines, along with what it took to build a company around a mission many initially believed was impossible. 🎧 Tune in to hear the full conversation on AI-powered cancer care, patient empowerment, and the future of real-world data in oncology: https://lnkd.in/eYMgfSm5 #OutcomesRocket #ClinicalTrials #PrecisionOncology #CancerCare #HealthTech #AI #DigitalHealth #Oncology #PatientAccess Selin Kurnaz, PhD | Arturo LoAIza-Bonilla MD | Çağatay M. Çulcuoğlu